New Zealand markets closed
  • NZX 50

    11,636.76
    -17.80 (-0.15%)
     
  • NZD/USD

    0.6377
    +0.0003 (+0.04%)
     
  • NZD/EUR

    0.6057
    +0.0005 (+0.08%)
     
  • ALL ORDS

    7,502.20
    -51.80 (-0.69%)
     
  • ASX 200

    7,299.60
    -54.80 (-0.75%)
     
  • OIL

    81.34
    +0.12 (+0.15%)
     
  • GOLD

    1,812.40
    -2.80 (-0.15%)
     
  • NASDAQ

    12,041.89
    +11.83 (+0.10%)
     
  • FTSE

    7,558.49
    -14.56 (-0.19%)
     
  • Dow Jones

    34,395.01
    -194.76 (-0.56%)
     
  • DAX

    14,490.30
    +93.26 (+0.65%)
     
  • Hang Seng

    18,628.39
    -108.05 (-0.58%)
     
  • NIKKEI 225

    27,739.22
    -486.86 (-1.72%)
     
  • NZD/JPY

    86.1620
    -0.0030 (-0.00%)
     

KalVista Pharmaceuticals to Present at the 2022 HAEi Global Leadership Workshop

- Data provides patient perspectives on optimal treatment outcomes and quality-of-life challenges for people living with HAE -

CAMBRIDGE, Mass. & SALISBURY, England, September 30, 2022--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2022 HAE International (HAEi) Global Leadership Workshop taking place in Frankfurt, Germany from October 6-9. The presentations are:

  • Patient Perspectives on an Optimal Outcome Measure to Assess Efficacy in the Acute Treatment of Hereditary Angioedema Attacks: Marc A. Riedl, Danny M. Cohn, Emel Aygören-Pürsün, Andrea Zanichelli, Henriette Farkas, Jonathan A. Bernstein, William R. Lumry, Michael D. Smith, Christopher M. Yea, Paul K. Audhya. Results shared as a poster presentation and Q&A

  • The Global and Regional Impact of Hereditary Angioedema (HAE) Attacks on Mental Health, Activities of Daily Living and Quality of Life: Paula J. Busse, Teresa Caballero, Sally van Kooten, Sherry Danese, Ledia Goga. Results shared during the "Normalising HAE Patient lives’ session

Both presentations will take place on Level E1 in the SKYLOFT meeting room on Friday, October 7 from 2:30 – 3:30 CET.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing sebetralstat as an oral on-demand therapy for HAE attacks and is enrolling the Phase 3 KONFIDENT clinical trial. KVD824 is in development for prophylactic treatment of HAE, with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

For more information about KalVista, please visit www.kalvista.com.

For more information on the sebetralstat HAE on-demand Phase 3 KONFIDENT study, please visit www.konfidentstudy.com.

For more information on the KVD824 HAE prophylaxis Phase 2 KOMPLETE study, please visit www.kompletestudy.com.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including the potential impact of COVID-19, that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 3 KONFIDENT and Phase 2 KOMPLETE clinical trials, and to obtain regulatory approvals for sebetralstat, KVD824 and other candidates in development, the ability of sebetralstat, KVD824 and other candidates in development to treat HAE or DME, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2022, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220930005137/en/

Contacts

KalVista Pharmaceuticals, Inc.
Jarrod Aldom
Vice President, Corporate Communications
(201) 705-0254
jarrod.aldom@kalvista.com